BioCardia (BCDA) vs Estrella Immunopharma (ESLA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
BioCardia (BCDA) has outperformed Estrella Immunopharma (ESLA) over the past year, losing 25.4% versus a loss of 67.9%. Over five years, ESLA leads with a -95.8% price change compared with -97.6% for BCDA. Estrella Immunopharma is the larger company by market cap ($18.2 million vs $16.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCDA | ESLA |
|---|---|---|
| Share price | $1.06 | $0.4175 |
| Market cap | $16.05M | $18.16M |
| 1-day change | -2.75% | -0.43% |
| YTD return | -15.20% | -73.24% |
| 1-year return | -25.35% | -67.88% |
| 5-year return | -97.59% | -95.77% |
| EPS (TTM) | $-0.64 | $-0.25 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.80 | $3.15 |
| 52-week low | $0.75 | $0.3611 |
| Distance from 52-week high | -41.11% | -86.75% |
| Average volume | 288.86K | 38.27K |
| Shares outstanding | 15.14M | 43.50M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BCDA has outperformed ESLA by 42.5 percentage points over the past year.
BCDA vs ESLA FAQ
Which is bigger, BioCardia or Estrella Immunopharma?
Estrella Immunopharma (ESLA) is larger, with a market capitalization of $18.16M compared with $16.05M for BioCardia (BCDA).
Which stock has performed better over the past year, BCDA or ESLA?
BCDA returned -25.35% over the past 12 months, compared with -67.88% for ESLA (price return, excluding dividends). Past performance does not predict future results.
Are BioCardia and Estrella Immunopharma in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.